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Abstract: Three known triterpenoids, namely ursolic acid (1), and the 27-E- and 27-Z-p-
coumaric esters of ursolic acid (compounds 2, 3), were isolated together with a new 
triterpene 2,3-seco-taraxer-14-en-2,3-lactone [pycanocarpine (4)] from an ethanolic extract 
of Pleiocarpa pycnantha leaves. The structure of 4 was unambiguously assigned using 
NMR, HREIMS and X-ray crystallography. The cytotoxic activities of the compounds 
were evaluated against HeLa, MCF-7, KMST-6 and HT-29 cells using the WST-1 assay. 
Ursolic acid (1) displayed potent cytotoxic activity against HeLa, HT-29 and MCF-7 cells 
with IC50 values of 10, 10 and 20 µM respectively. The new compound 4 and its 
hydrolysed derivative 5 were selectively cytotoxic to the breast cancer cell line, MCF-7 
with IC50 values 20 and 10 µM respectively. This is the first report on isolation of a  
2,3-seco-taraxerene derivative from the Apocynaceae family and cytotoxic activityof  
P. pycnantha constituents. 
Keywords: Pleiocarpa pycnantha; Apocynaceae; triterpenoids; cytotoxicity;  
2,3-seco-taraxerene; ursolic acid; WST-1 
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1. Introduction 
Man has used plants for food and medicinal purposes for thousands of years and thereby has 
acquired detailed knowledge of their properties [1–3]. Medicinal plants have been in use to treat 
various diseases for many years in different parts of the world [4]. The use of natural products is also 
on the increase in the Western world [5]. These natural products are used either as standardized plant 
extract, semi purified or purified forms [6]. According to the World Health Organization [7], about 
70%–95% of the world’s population in developing countries relies mainly on plants for their primary 
health care. Traditional medicine remains the only health resource available to about 60% of the 
world’s population, especially those in the vast rural areas of developing countries [8,9]. 
Cancer is a major public health burden in both developed and developing countries. According to 
the global cancer statistics made public by the American Cancer Society in 2007, the total number of 
cancer deaths per day was 20,000 with 38% in developed countries and 62% in developing countries. 
It was also projected that 27 million new cancer cases and 17.5 million cancer deaths would occur by 
2050. Siegel et al. [10] performed one of the most recent studies on cancer incidence, mortality, and 
survival based on incidence from the National Cancer Institute, the Centers for Disease Control and 
Prevention, and the North American Association of Central Cancer Registries and mortality data from 
the National Center for Health Statistics. A total of 1,638,910 new cancer cases and 577,190 deaths 
from cancer were projected to occur in the United States in 2012. Plants have a long history of use in 
in cancer treatment [11]. Over 60% of currently used anticancer agents are derived from natural 
sources [12,13]. Traditionally, Apocynaceae plants were used to treat gastrointestinal ailments, fevers, 
malaria, pain, diabetes, ulcers, tuberculosis, helminthosis and cancer [14–19]. Pleiocarpa pycnantha is 
a shrub or small to large tree attaining of highest up to 30 m in secondary jungle or in the lower level 
of the high-forest from Mali to South Nigeria and across Africa to Zaire, Angola, Uganda and 
Zanzibar. The wood is hard and yellow, and it’s used to make combs, plane-blocks and sundry small 
objects. In Ghana, the roots are added to palm-wine to give it potency. Ground roots mixed with seeds 
of Aframomum melegueta K. Schum. and palm wine is taken as a laxative. In Benin, leaf maceration 
with lemon juice is given to patients suffering from jaundice, oedema, reduced urine excretion and 
infection by roundworms [20]. In the Yoruba speaking part of West Africa a blend of the leaves of  
P. pycnantha, Spondias mombin (Anacardiaceae) and a fruit of Aframomum melegueta (Zingiberaceae), 
are combined and administered to gain and retain good memory [21]. Some indole alkaloids e.g., 
pycnanthine, pleiocarpamine, quebrachamine macusine and (−)-ebunarmine have been isolated from  
P. pycnantha roots and bark [22,23]. Pleiocarpamine has demonstrated anticancer potential [24]. In 
this work, we explored the anticancer potential of P. pycnantha, its extracts and isolated compounds. 
To the best of our knowledge, this is the first substantial biological activity reported for P. pycnantha 
leaves and the first on isolation of triterpenes for the specie, and the second for the genus. 
2. Results and Discussion 
An ethanol extract of P. pycnantha leaves was evaluated for cytotoxicity on cervical carcinoma 
(HeLa), breast adenocarcinoma (MCF-7), colorectal adenocarcinoma (HT-29) and non-cancerous 
fibroblast (KMST-6) human cell lines, the extract treatment induced loss of cell viability in a  
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dose-dependent manner. However the activity was low with IC50 > 100 µg/mL on all the cell lines, 
some of the fractions demonstrated potent activity at <100 μg/mL, which gave some justification to 
carry out further chemical investigations of such fractions. The active fractions were further purified 
which led to the isolation of the active constituents 1–4 (Figure 1). Repeated chromatography of the 
fractions P4, P9 and P12 led to the isolation of three known triterpenoids; ursolic acid (1) [25,26],  
27-p-E-coumaroloxyursolic acid (2) [27], 27-p-Z-coumaroyloxyursolic acid (3) [28], and a new 
triterpene, which we have named pycanocarpine (4), which was further hydrolyzed to give the 
corresponding 2-carboxy-3-hydroxy derivative 5. The known compounds were identified by comparison 
of their NMR data with published values [25–28]. 
Figure 1. Chemical structures of isolated compounds from P. pycnantha. 
 
Triterpene esters containing the E-coumaric acid isomer have been reported from natural sources, 
while, the co-existence of E- and Z-coumaric acid esters of ursolic acid (compounds 2 and 3) in 
Plumeria obtusa of the same family has been reported once [27,28]. However, although some reports 
have indicated the photo isomerization of the E isomers to the Z form using UV light [29], we did not 
observe any such change (as indicated by 1H-NMR measurements) in any of the isomers during  
2–3 months under normal working conditions. 
Compound 4 was isolated as colourless needle-like crystals with molecular formula of C30H48O2 on 
the basis of TOF-ESI-MS m/z 441.3735[M+H]+. The IR spectra showed peaks at 1,738 cm−1 (C=O 
stretching) and 1,474 cm−1 (C-O). The NMR spectroscopic data of 4 are similar to those of 3β-taraxerol, 
with differences limited to ring A. The signal due to the olefinic proton at δ 5.54 (m) together with  
13C-NMR signals of C-14 (δ 157.7) and C-15 (δ 117.1) suggested a taraxerane moiety [30]. The signal 
at δ 174.8 (C-2), 77.9 (C-3) in addition to oxygenated methylene protons at δ 3.79 and 4.08 (CH2-3) 
indicated the presence of a lactone group. The ring A of compound 4 showed some similarity when it 
was compared to 4-hydroxy-3,4-seco-ursan-12-en-28-oic acid 3,4 lactone derived from ursolic acid [31] 
and compared very favourably. The NMR data were assigned unambiguously from 2D NMR spectral 
analysis of compound 4 and its hydrolyzed product 5. The structure was finally established from X-ray 
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diffraction studies. Figure 2 illustrates the perspective view of the molecule with its relative 
configuration. The compound was thus assigned as 2,3-seco-taraxer-14-en-2,3-lactone and given the 
name pycanocarpine. After alkaline hydrolysis, compound 4 produced the unstable derivative viz  
2,3-seco-3-hydroxy-taraxer-14-en-3-oic acid (5) as an off-white amorphous powder. The TOF-ESI-MS 
indicated an m/z 459.3889 [M+H]+. It was noticeable that the free carboxylic and hydroxyl groups 
would easily reform the lactone ring after a short time in organic solvents such as methanol and 
chloroform. The NMR data of 5 is similar to the parent compound 4 and is illustrated in Table 1. 
Minor changes were observed between 4 and 5 for carbons C-11, -23, -24, and -26. The 
stereochemistry of both compounds, especially ring A, may partially explain this. In 4 the carbonyl 
group is directed into the same plan similar to C-24, -26 and -11. On the other hand, in derivative 5, 
the minimized energy conformation (Figure 3) showed different orientations and distances for the  
C3-OH and C2OOH groups. 
Figure 2. ORTEP diagram for 4. 
 
Table 1. ¹H/¹³C-NMR data of 4 (CDCl3) and 5 (CDCl3+ 1drop CD3OD) (δ values, J in 
parenthesis in Hz). 
Position Compound 4 Compound 5 13C 1H (J Hz) 13C 1H (J Hz) 
1 44.9 t 2.44 br s; 2.78 br s 43.1 t 2.36 d, 2.35 d, (12.0) 
2 174.8 s ----- 172.9 s ----- 
3 77.9 t 3.79 br s; 4.08 br s 72.1 t 3.33 d; 3.34 d, (7.0) 
4 38.4 s ----- 38.6 s ----- 
5 48.7 d 0.97 * 44.9 d 1.72 * 
6 20.6 t 1.57 *; 1.66 * 21.8 t 1.60 *; 1.53 * 
7 35.1 t 1.02 *; 1.35 * 35.6 t 0.95 *; 1.34 * 
8 35.8 s ----- 34.9 s ----- 
9 40.9 d 1.64 * 42.8 d 1.76 * 
10 46.7 s ----- 43.6 s ----- 
11 18.6 t 1.57 *; 1.75 br s 29.5 t 1.18 * (2H) 
12 36.6 t 0.98 (dd; 12.0, 4.5); 1.34 * 37.5 t 1.49 *; 1.83 (td; 9.0, 3.5) 
13 37.4 s ----- 37.0 s ----- 
14 157.5 s ----- 157.3 s ----- 
15 117.1 d 5.54 (dd; 8.0, 3.5) 116.8 d 5.46 dd, (9.0, 4.5) 
16 37.8 t 1.64 *; 1.92 (dd; 9.0, 2.0) 36.5 t 0.90 *; 1.22 * 
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Table 1. Cont. 
Position Compound 4 Compound 5 13C 1H (J Hz) 13C 1H (J Hz) 
17 40.6 s ----- 40.2 s ----- 
18 48.7 d 0.97 * 48.5 d 0.92 * (2H) 
19 39.4 t 1.37 *; 2.04 (dt; 9.5, 3.5) 39.7 t 1.33*; 1.96 (dd; 3.5, 8.5) 
20 28.7*s ----- 28.6 s ----- 
21 33.1 t 1.25 (dt; 9.5, 3.2); 1.32 * 32.9 t 1.44 *; 1.59 * 
22 33.6 t 1.60 *; 1.64 * 33.8 t 1.55 *; 1.60 * 
23 19.4 q 1.02 s 26.3 s 0.93 s 
24 28.7 q 0.95 s 24.4d 1.04 s 
25 17.5 q 1.13 s 18.5 q 1.02 s 
26 25.8 q 1.11 s 20.6 q 0.86 s 
27 29.6 q 0.92 s 29.5 q 0.83 s 
28 21.1 q 0.90 s 23.9 q 1.00 s 
29 33.5 q 0.95 s 33.1 q 0.87 s 
30 29.6 q 0.83 s 29.7 q 0.71 s 
* overlapped signals. 
Figure 3. Ball and Stick minimized energy model for 5. 
 
The five compounds 1–5 were examined for their dose-response effect on the viability of HeLa,  
HT-29, MCF-7 and KMST-6 cells using the WST-1 assay (Figure 4). All the compounds isolated from 
P. pycnantha leaves inhibited the growth of cancer cell on specific cell lines except 4 from fraction P4 
which did not show cytotoxicity on HeLa and HT-29 cells at the dosages used in this study. The 
cytotoxicity activity ranged from low to moderate to high. The results from the WST-1 assay were 
used to determine the IC50 values for all the compounds on the four cell lines. Generally, the highest 
cytotoxicity was demonstrated by ursolic acid (1) with an IC50 value of 10 μM on HeLa and HT-29 
cells and 20 μM on MCF-7 cells (Table 2). Compound 2 was moderately cytotoxic with IC50 values of 
50, 100 and 60 μM on HeLa, MCF-7, and HT-29 respectively (Table 2). Compounds 3 and 4 were 
weakly cytotoxic on all cancer cell lines and non- cytotoxic to the non-cancerous cell line KMST-6. 
The IC50 value of 3 ranged from 180 μM to 300 μM on the cancer cells. The new compound 4 
displayed cytotoxicity to the adenocarcinoma cell line, MCF-7 with an IC50 value of 20 μM while it 
was non cytotoxic on other cell lines, including the non-cancerous cell line KMST-6. The selectivity 
index (SI) for 4 was > 30 for MCF-7 cells, demonstrating that the activity of this compound is highly 
selective for MCF-7 cells. Compound 5 was also highly cytotoxic to MCF-7 cells and the  
non-cancerous KMST-6 cells with IC50 value of 10 μM. Compound 5 was only moderately cytotoxic 
on HeLa and HT-29 cells with IC50 values of 180 μM and 170 μM, respectively. Generally, the IC50 
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values for ursolic acid (1) on all cell lines tested in this study was lower compared to 2 and 3. This is 
an indication that ursolic acid was more cytotoxic than its 27-ester derivatives. A similar trend was 
observed by Shao et al. [32] where it was suggested that the introduction of bulky groups containing 
benzene to the 3-OH position could increase the steric hindrance and decrease binding to the target. 
Figure 4. Effect of compounds 1–5 on cell viability of (A) HeLa cells (B) HT-29  
(C) MCF-7 (D) KMST-6 in a concentration dependent manner as measured by WST-1 assay. 
 
Table 2. IC50 (μM) values for compounds 1–5 as determined by WST-1 assay. 
Compound 
Cell lines 
HeLa HT-29 MCF-7 KMST-6 
IC50 SI IC50 SI IC50 SI IC50 
1 10 10.0 10 10.0 20 5.0 100 
2 50 2 100 1 60 1.7 100 
3 200 1.5 230 1.3 180 1.7 300 
4 >600 ----- >600 ----- 20 >30 >600 
5 180 0.06 170 0.06 10 1 10 
Selectivity Index (SI) = IC50(KMST-6)/IC50(HeLa) or any of the cancer cell lines used. 
Cancer being the second largest disease makes a sizeable contribution to the total number of deaths. 
The World Cancer Report documented that cancer rates are set to increase globally at an alarming  
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rate [33]. Plants usage has been the basis of prevention and treatment of diseases for centuries and it is 
thus not surprising that development of anticancer drugs today started from their preliminary 
cytotoxicity screening. Ursolic acid (1) is an ursane type triterpene found mainly in the leaves and 
displays several important biological activities viz: anti-inflammatory, antioxidant and anti-cancer 
properties [34]. Compound 3 has been reported to have potent activity against acetyl CoA cholestryl 
acyl tranferase (ACAT) [35]. The anti-proliferative activity of ursolic acid (1) has been reported in a 
wide variety of cancer cell lines [36]. Ursolic acid hydroxycinnamate esters isolated from cranberry 
fruit has been evaluated for anti-tumour activity in a 60 tumour cell line panel through the  
National Cancer Institute’s Developmental Therapeutics program. The research showed that the esters 
inhibited the growth of lung, colon, breast, renal and leukemia cancer cell lines with GI50 ranging from  
1.2–11 µM based on sulforhodamine B(SRB) assay [37]. The cis- and trans- isomers of  
3-O-p-hydroxycinnamoyl ursolic acid has been reported to inhibit tumour growth in vitro with the  
cis-3-O-p-hydroxycinnamoyl ursolic acid showing slightly greater activity in most cell lines with GI50 
values ~20 µM in MCF-7 breast, ME 180 cervical, and PC3 prostate tumour cell lines [38]. The  
anti-proliferative activity hydroxycoumaroyl esters of ursolic acids were reported on A-549, HCT-15, 
MCF-7, HT-1197 with IC50 ranging from 0.5 to 6.5 µg/mL, from Uncaria rhynchophylla [39]. Many 
plants from Apocynaceae family have been reported for anticancer activity [40], including this report, 
which indicated the importance of their constituents as an interesting source for the discovery of new 
anticancer agents. 
3. Experimental 
3.1. General 
NMR Spectra were measured on 200 Gemini-Varian (Varian Associates Inc., Palo Alto, CA, USA) 
and 400 MHz Bruker (Bruker BioSpin Corporation, Billerica, MA, USA) NMR spectrometers and the 
chemical shifts were expressed in ppm relative to CDCl3 signal (7.24 ppm for 1H, and 77.00 ppm for 
13C). TOF-ESI-MS spectra were measured using a HP-5 ms (30 m × 0.25 mm ID, 0.25 µm film 
thickness) column on a Waters GCT system (Waters Corporation, Milford, MI, USA) equipped with a 
CTC CombiPAL Autosampler (Agilent Technologies, Santa Clara, CA, USA). IR spectra were 
recorded on a Perkin Elmer Spectrum 400 spectrometer (PerkinElmer, MA, USA). An Agilent 1100 
HPLC system (Agilent Technologies, Santa Clara, CA, USA) consisting of a quaternary solvent 
delivery system, an on-line degasser, an auto-sampler, a column temperature controller and ultraviolet 
detector coupled with an analytical workstation and Discovery® C18 column, 5 μm, 250 mm × 10 mm 
i.d. (Sigma-Aldrich, St. Louis, MO, USA). TLC was performed on normal phase Merck Silica gel  
60 F254 on pre-coated aluminium plates (0.2 mm; Merck, Dermstadt, Germany). Column 
chromatography was carried out using 60 Å silica gel (230–400 mesh; Merck). 
3.2. Plant Material 
Pleiocapa pycnantha (K. Schum.) Stapf was collected in Ikere Ekiti, Ekiti State, Nigeria in 
December, 2010. The botanical identification was done by Femi Omotayo of the Herbarium section of 
Molecules 2014, 19 3396 
 
Plant Science Department of Ekiti State University, Ado-Ekiti, Nigeria, where a voucher specimen  
was deposited. 
3.3. Extraction and Isolation 
The ground air-dried leaves (~1.0 kg) were soaked in 95% ethanol for three days and the extract 
then filtered and concentrated in vacuum at ~ 40 °C to yield 81.0 g of the extract. Part (62.0 g) of the 
total extract was applied on silica gel column and eluted with a mixture of hexane-EtOAC of 
increasing polarity. Fractions showing similar TLC characteristics were pooled together and 
concentrated in vacuum, giving rise to 1 3  fractions coded P 1–P 13 that were screened for 
cytotoxicity using WST-1 assay. Fraction P4, P7, P8 and P9 displayed strong cytotoxicity while P12 
was moderately cytotoxic and were submitted for further purification. P9 (4.0 g) was chromatographed 
on a silica gel column using gradient elution with EtOAc/hexane (20:80–100:0) to afford Q1-13; Q4 
(310 mg) was crystallized from 10% hexane/EtOAc to give compound 1 (100 mg). P12 (5.2 g) was 
chromatographed on silica gel column using EtOAc/hexane (50:50–100:0) to afford sub-fraction A-H. 
P12E (140 mg) was further purified on sephadex LH-20 column using DCM/MeOH(95:5) and HPLC 
(MeOH/H2O,80:20) to afford compound 2 (5.5 mg) and 3 (7.3 mg). Fraction P4 (6.0 g) was 
chromatographed on silica gel using EtOAc/hexane (2:98–100:0) to give T1–T10, sub-fraction T6 was 
recrystallized from hexane to produce compound 4 (0.97g). Compound 5 was synthesized by refluxing 
33.0 mg of 4 in methanolic/KOH (5.0%) for 3 h to afford R1 mixture which was purified on silica gel 
column using hexane/EtOAC (70:30) to yield 20 mg (60%). 
3.4. Spectra Data 
Pycanocarpine (4). Needle-like crystals, mp 246–249 °C; IR (KBr) Vmax 3054, 2914, 2856, 1738, 
1474, 1077 cm−1. TOF-ESI-MS m/z 441.3735 [M+H]+ (calcd 440.3654 for C30H48O2);1H and 13C-NMR 
data see Table 1. 
2,3-Seco-3-hydroxy-taraxer-14-en-3-oic acid (5); Off-white amorphous powder, mp 237–241 °C;  
IR (KBr) Vmax 3055, 2921, 2857, 1740, 1473, 1067cm−1; TOF-ESI-MS m/z 459.3889 [M+H]+  
(calcd 458.3760 for C30H50O3); 1H and 13C-NMR data see Table 1. 
3.5. X-ray Structure Determination of 4 
Single-crystal X-ray diffraction data [41] were collected on a Bruker KAPPA APEX II DUO 
diffractometer (Bruker BioSpin Corporation, Billerica, MA, USA)) using graphite-monochromated 
Mo-K radiation ( = 0.71073 Å). Data collection was carried out at 173(2) K. Temperature was 
controlled by an Oxford Cryostream cooling system (Oxford cryosystems Ltd, Oxford, UK). Cell 
refinement and data reduction were performed using the program SAINT [42]. The data were scaled 
and absorption correction performed using SADABS [43]. 
The structure was solved by direct methods using SHELXS-97 and refined by full-matrix  
least-squares methods based on F2 using SHELXL-97 [43] and using the graphics interface program 
X-Seed [44,45]. The programs X-Seed and POV-Ray [46] were both used to prepare molecular 
graphic images. All non-hydrogen atoms were refined anisotropically. All hydrogen atoms were placed 
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in idealised positions and refined in riding models with Uiso assigned the values to be 1.2 or 1.5 times 
those of their parent atoms and the constraint distances of C-H ranging from 0.95 Å to 1.00 Å. The 
structure was refined to R factor of 0.0483. The Flack × parameter is equal to −0.0123 with 1.3609. 
3.6. Culture of Cell Lines 
HeLa, HT-29, MCF-7 and KMST-6 cells were prepared from our laboratory stocks. Briefly, cell 
monolayers were maintained in Dulbecco’s modified Eagle’s (DMEM, Lonza Group Ltd., Base, 
Switzerland) medium with phenol red supplemented with 10% foetal bovine serum (FBS, Biochrom 
AG, Berlin, Germany) and 1% Penicillin–streptomycin (Lonza Group Ltd.). All cells were maintained 
in a humidified incubated at 37 °C in an atmosphere of 5% CO2. The cells were harvested using 
trypsin (Lonza Group Ltd.), and viable cell concentrations were determined using the Countess® 
Automated Cell Counter (Invitrogen, CA, USA). 5 × 104 viable cells were added to each well of a  
96-well tissue culture plate and incubated overnight at 37 °C under 5% CO2 in a humidified incubator 
to allow cells to attach to wells. 
3.7. WST-1 Based Cytotoxicity Assay 
Cell viability was measured using the WST-1 assay (Roche Diagnostics GmbH, Mannheim, 
Germany) as previously described by Ngamwongsatit et al., 2008. Cells were plated in 96-well cell 
culture plates at a concentration of 5 × 104 cells/well in 100 µL culture medium. After 24 h the cells 
were treated with increasing concentrations of ethanol extract (0–2 mg/mL), fractions (0–2 mg/mL) 
and purified compounds (0–250 µg/mL) for a further 24 h. The extracts, fractions and compounds 
were prepared in DMSO and then mixed with the culture medium. The final concentrations of the 
DMSO were less than 0.1%. Following 24 h treatment, 10 µL of cell proliferation reagent WST-1 was 
added and the plates were incubated for 4 h at 37 °C under 5% CO2 in a humidified incubator. The  
plates wereshakenfor 1 min on a shaker and the absorbance of the samples were measured at 450 nm 
(reference wavelength was 750 nm) on a micro-plate reader. The cell viability was calculated using the 
following formula: 
% Viability = ODtreated well − ODblank/ODuntreated well − ODblank (1)
IC50 values were calculated using Prism Graph pad software. Triplicate experiments were conducted 
and the results expressed as mean ± SEM. 
4. Conclusions 
The phytochemical study of the ethanolic extract from the leaves from Pleiocarpa pycnantha has 
led to the isolation a new traxerane-type triterpenoid, in addition to three known compounds. 2,3-Seco 
triterpenoids are rare in Nature and compound 4 represents the first example of this type to be isolated 
from the Apocynaceae family. This is the first report of the isolation of triterpenes from the plant and 
to the best of our knowledge, the first significant bioactivity report. Our studies suggested that pure 
compounds isolated from Pleiocarpa pycnantha demonstrate cytotoxic activity against cervical, breast 
and colon cancer. 
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